Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04398316 · ClinicalTrials.gov registry record · Phase 4
High Dose IV Lidocaine vs Hydromorphone for Abdominal Pain in the Emergency Department
A Phase 4 study, sponsored by Hennepin Healthcare Research Institute.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT04398316 is a Phase 4 study that was terminated before completion, run by Hennepin Healthcare Research Institute. The registered enrollment target is 4 participants.
The verdict
NCT04398316, a Phase 4 study, was terminated before completion, sponsored by Hennepin Healthcare Research Institute.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
Intravenous lidocaine will be given at a dose of 2 mg/kg intravenously to patients in the emergency department with a diagnosis of acute abdominal pain. Its efficacy will be compared to 1 mg of intravenous hydromorphone, with a primary endpoint of mean improvement of pain at 90 minutes.
Interventions
- DRUG Lidocaine Iv
- DRUG HYDROmorphone Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-02-18 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04398316
The ClinicalTrials.gov registry entry for NCT04398316 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hennepin Healthcare Research Institute, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lidocaine Iv is the first listed.
NCT04398316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04398316 about?
NCT04398316 is a clinical study titled "High Dose IV Lidocaine vs Hydromorphone for Abdominal Pain in the Emergency Department". Intravenous lidocaine will be given at a dose of 2 mg/kg intravenously to patients in the emergency department with a diagnosis of acute abdominal pain. Its efficacy will be compared to 1 mg of intravenous hydromorphone, with a primary endpoint of mean improvement of pain at 90 minutes.
What is the current status of trial NCT04398316?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2021-02-18. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT04398316?
The interventions under investigation include: Lidocaine Iv (DRUG), HYDROmorphone Injection (DRUG).
Who is sponsoring clinical trial NCT04398316?
This trial is sponsored by Hennepin Healthcare Research Institute, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.